Buy Rating on Sarepta Therapeutics Upheld Due to Elevidys’ Promising Efficacy and Safety Data
Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target ...
Buy Rating on Sarepta Therapeutics: Promising Long-Term Data and Market Opportunity Amid Stock Weakness
Analyst Gena Wang of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...
Capricor reports positive long-term data for DMD drug deramiocel
Capricor Therapeutics (NASDAQ:CAPR) stock rose 5% in midday trading Friday after the company reported positive long-term data ...
STAT14h
A setback for the Denali-Sanofi partnership
Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...
bovnews15h
What’s Driving Sarepta Therapeutics Inc (SRPT) Stock’s -4.66% Plunge Over the Past Month?
On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...